You are here:

brivaracetam (Briviact)

Advice

following a full submission:

brivaracetam (Briviact®) is accepted for restricted use within NHS Scotland.

Indication under review: Adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adult and adolescent patients from 16 years of age with epilepsy.

SMC restriction: for use in patients with refractory epilepsy and treatment should be initiated by physicians who have appropriate experience in the treatment of epilepsy.

In a pooled analysis of three fixed-dose, placebo-controlled, phase III studies there were statistically significant reductions in the frequency of partial-onset seizures with brivaracetam versus placebo.

Drug Details

Drug Name: brivaracetam (Briviact)
SMC Drug ID: 1160/16
Manufacturer: UCB Pharma Ltd
Indication: Adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adult and adolescent patients from 16 years of age with epilepsy.
BNF Category:
Sub Category: 4.8 Antiepileptic drugs
Submission Type: Full submission
Status: Restricted
Date Advice Published: 11 July 2016

Back